We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1–6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study / Orditura, M; Galizia, G; Napolitano, V; Martinelli, E; Pacelli, Roberto; Lieto, E; Aurilio, G; Vecchione, L; Morgillo, F; Catalano, G; Ciardiello, F; Del Genio, A; Di Martino, N; De Vita, F.. - In: CANCER INVESTIGATION. - ISSN 0735-7907. - STAMPA. - 28:8(2010), pp. 820-827. [10.3109/07357901003630926]
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.
PACELLI, ROBERTO;
2010
Abstract
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1–6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cancer Investigation6.pdf
non disponibili
Tipologia:
Documento in Pre-print
Licenza:
Accesso privato/ristretto
Dimensione
152.54 kB
Formato
Adobe PDF
|
152.54 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
